Recce

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

Retrieved on: 
Thursday, February 29, 2024

In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.

Key Points: 
  • In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.
  • “The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance.”
    The collaboration between Recce’s AIR Unit and MCRI exemplifies the power of partnership in driving medical breakthroughs.
  • As both organizations work together to advance anti-infective research, they remain committed to improving patient outcomes and addressing global health challenges.
  • James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Recce Pharmaceuticals Announces Results of Entitlement Offer

Retrieved on: 
Tuesday, October 3, 2023

SYDNEY, Australia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), the Company developing a new class of synthetic anti-infectives, announced today the completion of an entitlement offer to shareholders raising approximately $2.7 million before costs.

Key Points: 
  • SYDNEY, Australia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), the Company developing a new class of synthetic anti-infectives, announced today the completion of an entitlement offer to shareholders raising approximately $2.7 million before costs.
  • The Company has raised approximately $10.7 million before costs through the entitlement offer and placement to institutional, sophisticated, and professional investors completed on September 18, 2023 (Placement).
  • Under the terms of the entitlement offer, eligible shareholders were invited to apply for one new fully paid ordinary share in the Company (New Share) at an issue price of $0.44 per new share, the same offer price as the placement, for every 26 existing fully paid ordinary shares in the Company (Shares) held at 7:00 p.m. AEST on Thursday, September 14, 2023 (Record Date) to raise approximately $3M before costs and provided shareholders the opportunity to apply for additional new shares above their entitlement offer.
  • The entitlement offer was announced on Monday, September 11, 2023, and closed at 5:00 p.m. AEST on Wednesday, September 27, 2023, the results of which are as follows:

Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders

Retrieved on: 
Wednesday, September 13, 2023

“We are thrilled to receive such strong financial interest, particularly among global investment funds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “We are thrilled to receive such strong financial interest, particularly among global investment funds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Each of the Directors of the Company intends to subscribe for their respective entitlement partially or in full under the entitlement offer.
  • Any new shares not applied for under the entitlement offer and any entitlements that would have been offered to ineligible shareholders if they had been entitled to participate in the offer will form part of the shortfall from the entitlement offer.
  • Further information in relation to the entitlement offer will be sent to eligible shareholders in the offer booklet and accompanying personalized entitlement and acceptance form, which are expected to be dispatched on Friday, September 15, 2023.

Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”

Retrieved on: 
Thursday, August 10, 2023

“Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs.
  • Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up.
  • Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments

Retrieved on: 
Friday, January 27, 2023

SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce a total research and development (R&D) cash receipt of A$6,219,241.

Key Points: 
  • SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce a total research and development (R&D) cash receipt of A$6,219,241.
  • The Australian Government’s 43.5% R&D Tax Incentive Rebate is typically reserved for Australian-based R&D only.
  • Recce was uniquely granted the ability to capture 43.5% of the Company’s R&D applicable activities overseas as well, as previously announced and reflected in this rebate.
  • The Company may utilize Radium’s services to access up to 80% of the anticipated R&D rebate accruing interest at the compounded rate of 1.25% per month.

Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Wednesday, January 11, 2023

SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”

Key Points: 
  • SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”
    “Receiving notice that this Australian patent application will proceed to grant is another milestone in the Company’s global IP strategy, and we are thrilled by the further validation of the potential importance of our infectious disease compounds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Australian Patent is expected to grant claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably:
    Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, (human immunodeficiency virus) HIV, hepatitis, Ross River and herpes viruses
    Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
    This is the final patent of family three (expiry: November 2037), following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe, Hong Kong, and the United States.

Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute

Retrieved on: 
Monday, December 19, 2022

SYDNEY, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children's). The agreement secures a dedicated research team of infectious disease experts and fit-for-purpose laboratory space with access to a library of clinical isolates and drug-resistant pathogens.

Key Points: 
  • Subsidised collaborative for tackling infectious diseases – cost-efficient studies, laboratory space provided at no additional cost
    SYDNEY, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced the commencement of an Anti-Infective Research (AIR) Unit through the execution of a research collaboration agreement with Murdoch Children’s Research Institute (Murdoch Children's).
  • “We are thrilled to enter this agreement with Murdoch Children's, as it will give Recce direct access to critical pre-clinical laboratory studies,” said Phil Sutton, Ph.D., Vice President of Translational Sciences of Recce Pharmaceuticals.
  • Murdoch Children’s Research Institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.
  • Based in Melbourne, one of the most innovative cities for world-leading medical research and development, the dedicated research within Recce’s AIR Unit will streamline ongoing pre-clinical programs and explore new research development opportunities.